Lannett's Generic Solifenacin Succinate Receives Approval in the U.S.
Aurobindo's Generic Sildenafil Citrate Receives Approval in the U.S.
Annora Pharma's Generic Solifenacin Succinate Receives Approval in the U.S.
Accord Healthcare's Generic Solifenacin Succinate Receives Approval in the U.S.
Cipla recalls 7,228 bottles of overactive bladder treatment drug in America
Enforcement Report - Week of July 21, 2021
Zydus Cadila has received final approval from the USFDA to market Solifenacin Succinate Tablets, (US RLD: Vesicare Tablets) in the strengths of 5 mg and 10 mg.
Drug firm Zydus Cadila on Tuesday said it has received final approval from the US health regulator to market Solifenacin Succinate tablets, used for treatment of overactive bladder.
SILVER SPRING, Md., May 26, 2020 /PRNewswire/ -- The U.S. Food and Drug Administration today granted approval to VESIcare LS (solifenacin succinate) oral suspension, a liquid taken by mouth, for the treatment of neurogenic detrusor overactivity (NDO), a form of bladder dysfunction related to neurological impairment, in children ages two years and older. VESIcare (solifenacin succinate) tablets were initially approved in 2004 for the treatment of overactive bladder in adults 18 years and older.